Metastatic osteogenic sarcoma showed limited response to adriamycin and cyclophosphamide. Escalating cyclophosphamide doses did not improve outcomes for advanced osteosarcoma patients.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: